Skip to main content
SpringerLink
Log in

Prognostic value of volumetric parameters measured by 18F-FDG PET/CT in patients with head and neck squamous cell carcinoma

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

The objective of this study was to investigate the value of metabolic tumour volume (MTV) assessed with 18F-FDG PET/CT in predicting event-free survival (EFS) and overall survival (OS) in patients with head and neck squamous cell carcinoma (HNSCC), and particularly to compare it with more conventional parameters such as maximum standardized uptake value (SUVmax).

Methods

Patients referred to our department for 18F-FDG PET/CT for staging of HNSCC were prospectively included between February 2009 and March 2011. Each patient was scanned using a Philips Gemini PET/CT system at 1 h after injection. The MTV was calculated semiautomatically for the primary site using methods based on SUV with various thresholds: 3-D contour around voxels equal to or greater than 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5 and 7.0 times SUV, or more than 30 %, 40 % and 50 % of SUVmax. ROC analysis was used to test the statistical significance of the differences among the calculated MTVs. EFS and OS were determined using the Kaplan-Meier method and compared with MTV in univariate and multivariate analyses, including the usual prognostic factors: age, sex, primary site, treatment, SCC histologic grade, AJCC stage, TNM classification, tumour SUVmax and SUVpeak.

Results

The study included 80 consecutive patients (70 men, 10 women; mean age 62.4 ± 9.0 years). ROC analysis revealed that pretreatment MTV using a threshold of 5.0 times SUV (MTV5.0) was the best parameter to predict recurrence and death after treatment. In univariate analysis, MTV5.0 >4.9 ml was predictive of poor EFS (p < 0.0001) and poor OS (p < 0.0001). In multivariate, MTV5.0 persisted as an independent predictive factor for EFS (p = 0.011) and OS (p = 0.010), while SUVmax became nonsignificant (p = 0.277 for EFS, p = 0.975 for OS).

Conclusion

Our results suggest that MTV measured by 18F-FDG PET/CT has independent prognostic value of in patients with HNSCC, stronger than SUVmax.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.

    Article  PubMed  Google Scholar 

  2. Ang KK, Trotti A, Brown BW, Garden AS, Foote RL, Morrison WH, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;51:571–8.

    Article  CAS  PubMed  Google Scholar 

  3. Leemans CR, Tiwari R, Nauta JJ, van der Waal I, Snow GB. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer. 1994;73:187–90.

    Article  CAS  PubMed  Google Scholar 

  4. Salaün PY, Abgral R, Querellou S, Couturier O, Valette G, Bizais Y, et al. Does 18fluoro-fluorodeoxyglucose positron emission tomography improve recurrence detection in patients cured of head and neck squamous cell carcinoma with negative clinical follow up? Head Neck. 2007;29:1115–20.

    Article  PubMed  Google Scholar 

  5. Abgral R, Querellou S, Potard G, Le Roux PY, Le Duc-Pennec A, Marianowski R, et al. Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med. 2009;50:24–9.

    Article  PubMed  Google Scholar 

  6. Cojocariu OM, Huguet F, Lefevre M, Périé S. Prognosis and predictive factors in head-and-neck cancers. Bull Cancer. 2009;96:369–78.

    CAS  PubMed  Google Scholar 

  7. Chiesa F, Mauri S, Tradati N, Calabreses L, Giugliano G, Ansarin M, et al. Surfing prognostic factors in head and neck cancer at the millennium. Oral Oncol. 1999;35:590–6.

    Article  CAS  PubMed  Google Scholar 

  8. Phelps ME, Huang SC, Hoffman EJ, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (18-F)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol. 1979;6:371–88.

    Article  CAS  PubMed  Google Scholar 

  9. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49:480–508.

    Article  PubMed  Google Scholar 

  10. Bourguet P, Blanc-Vincent MP, Boneu A, Bosquet L, Chauffert B, Corone C, et al. Summary of the Standards, Options and Recommendations for the use of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose (FDP-PET scanning) in oncology (2002). Br J Cancer. 2003;89:84–91.

    Article  Google Scholar 

  11. Halfpenny W, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M. FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer. 2002;86:512–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Allal AS, Dulguerov P, Allaoua M, Haengelli CA, el El-Ghazi A, Lehmann W, et al. Standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol. 2002;20:1398–404.

    Article  CAS  PubMed  Google Scholar 

  13. Querellou S, Abgral R, le Roux PY, Nowak E, Valette G, Potard G, et al. Prognostic value of fluorine-18 fluorodeoxyglucose positron-emission tomography imaging in patients with head and neck squamous cell carcinoma. Head Neck. 2012;34:462–8.

    Article  PubMed  Google Scholar 

  14. Dibble EH, Alvarez AC, Truong MT, Mercier G, Cook EF, Subramaniam RM. 18F-FDG metabolic tumor volume and total lesion glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. J Nucl Med. 2012;53:709–15.

    Article  CAS  PubMed  Google Scholar 

  15. Moon SH, Hyun SH, Choi JY. Prognostic significance of volume-based PET parameters in cancer patients. Korean J Radiol. 2013;14:1–12.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Zhu D, Ma T, Niu Z, Zheng J, Han A, Zhao S, et al. Prognostic significance of metabolic parameters measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer. Lung Cancer. 2001;73:332–7.

    Article  Google Scholar 

  17. Hyun SH, Choi JY, Shim YM, Kim K, Lee SJ, Cho YS, et al. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with oesophageal carcinoma. Ann Surg Oncol. 2010;17:115–22.

    Article  PubMed  Google Scholar 

  18. Chung HH, Kwon HW, Kang KW, Park NH, Song YS, Chung JK, et al. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer. Ann Surg Oncol. 2012;19:1966–72.

    Article  PubMed  Google Scholar 

  19. Tang C, Murphy JD, Khong B, La TH, Kong C, Fischbein NJ, et al. Validation that metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2012;83:1514–20.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Van de Wiele C, Kruse V, Smeets P, Sathekge M, Maes A. Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours. Eur J Nucl Med Mol Imaging. 2013;40:290–301.

    Article  CAS  PubMed  Google Scholar 

  21. Chu KP, Murphy JD, La TH, Krakow TE, Iagaru A, Graves EE, et al. Prognostic value of metabolic tumor volume and velocity in predicting head-and-neck cancer outcomes. Int J Radiat Oncol Biol Phys. 2012;83:1521–7.

    Article  PubMed Central  PubMed  Google Scholar 

  22. La TH, Fillion EJ, Turnbull BB, Chu JN, Lee P, Nguyen K, et al. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009;74:1335–41.

    Article  PubMed Central  PubMed  Google Scholar 

  23. Choi KH, Yoo LR, Han EJ, Kim YS, Kim GW, Na SJ, et al. Prognostic value of metabolic tumor volume measured by 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinomas treated by surgery. Nucl Med Mol Imaging. 2011;47:43–51.

    Article  Google Scholar 

  24. Moon SH, Choi JY, Lee HJ, Son YI, Baek CH, Ahn YC, et al. Prognostic value of 18F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: comparison of volume-based metabolic parameters. Head Neck. 2013;35:15–22.

    Article  PubMed  Google Scholar 

  25. Kao CH, Lin SC, Hsieh TC, Yen KY, Yang SN, Wang YC, et al. Use of pretreatment metabolic tumor volumes to predict the outcome of pharyngeal cancer treated by definitive radiotherapy. Eur J Nucl Med Mol Imaging. 2012;39:1297–305.

    Article  PubMed  Google Scholar 

  26. Lim R, Eaton A, Lee NY, Setton J, Ohri N, Rao S, et al. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. J Nucl Med. 2012;53:1506–13.

    Article  CAS  PubMed  Google Scholar 

  27. Chung MK, Jeong HS, Park SG, Jang JY, Son YI, Choi JY, et al. Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res. 2009;15:5861–8.

    Article  CAS  PubMed  Google Scholar 

  28. Seol YM, Kwon YM, Kwon BR, Choi YJ, Shin HJ, Chung JS, et al. Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy. Acta Oncol. 2010;49:201–8.

    Article  CAS  PubMed  Google Scholar 

  29. Kim K, Kim SJ, Kim IJ, Kim YS, Pak K, Kim H. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer. Nucl Med Commun. 2012;33:613–20.

    Article  PubMed  Google Scholar 

  30. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, et al., editors. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010. p. 29–62.

  31. Sobin LH, Gospodarowicz MK, Wittekind C, editors. TNM Classification of Malignant Tumours. 7th ed. New York: Wiley-Liss; 2009.

  32. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers, V.2.2008. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 20 Nov 2008.

  33. Vanderhoek M, Perlman SB, Jeraj R. Impact of the definition of peak standardized uptake value on quantification of treatment response. J Nucl Med. 2012;53:4–11.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Higgins KA, Hoang JK, Roach MC, Chino J, Yoo DS, Turkington TG, et al. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value. Int J Radiat Oncol Biol Phys. 2012;82:548–53.

    Article  PubMed  Google Scholar 

  35. Schwartz DL, Ford E, Rajendran J, Yueh B, Coltrera MD, Virgin J, et al. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2005;61:129–36.

    Article  PubMed  Google Scholar 

  36. Wanet M, Lee JA, Weynand B, de Bast M, Poncelet A, Lacroix V, et al. Gradient-based delineation of the primary GTV on FDG-PET in non-small cell lung cancer: a comparison with threshold-based approaches, CT and surgical specimens. Radiother Oncol. 2011;98:117–25.

    Article  PubMed  Google Scholar 

  37. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24–35.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. Abgral R, Le Roux PY, Rousset J, Querellou S, Valette G, Nowak E, et al. Prognostic value of dual time point 18FDG PET-CT imaging in patients with head and neck squamous cell carcinoma. Nucl Med Commun. 2013;34:551–6.

    Article  CAS  PubMed  Google Scholar 

  39. Satoh Y, Nambu A, Onishi H, Sawada E, Tominaga L, Kuriyama K, et al. Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy. Eur J Radiol. 2012;81:3530–4.

    Article  PubMed  Google Scholar 

  40. Abe Y, Tamura K, Sakata I, Ishida J, Ozeki Y, Tamura A, et al. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma. Oncol Rep. 2012;27:333–8.

    CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, University Hospital of Brest, Boulevard Tanguy Prigent, 29200, Brest, France

    Ronan Abgral, Nathalie Keromnes, Philippe Robin, Pierre-Yves Le Roux, David Bourhis, Xavier Palard & Pierre-Yves Salaün

  2. Department of Radiology, Military Hospital of Brest, Brest, France

    Jean Rousset

  3. Department of Head and Neck Surgery, University Hospital of Brest, Brest, France

    Gérald Valette & Rémi Marianowski

Authors
  1. Ronan Abgral
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nathalie Keromnes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Philippe Robin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pierre-Yves Le Roux
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David Bourhis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xavier Palard
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jean Rousset
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gérald Valette
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Rémi Marianowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Pierre-Yves Salaün
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pierre-Yves Salaün.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abgral, R., Keromnes, N., Robin, P. et al. Prognostic value of volumetric parameters measured by 18F-FDG PET/CT in patients with head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging 41, 659–667 (2014). https://doi.org/10.1007/s00259-013-2618-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-013-2618-1

Keywords

Search

Navigation